Amneal launches generic Kenalog-40

Amneal Biosciences is launching its generic of Kenalog-40 (triamcinolone acetonide injectable suspension, 40 mg/ml), with the Food and Drug Administration approved Tuesday. Bridgewater, N.J.-based Amneal said that its generic would be the only one available for the product.

“This important launch demonstrates the depth of our ability to successfully develop and manufacture complex products in our state-of-the-art manufacturing facilities,” Amneal co-CEO and co-chairman Chirag Patel said.

Amneal’s generic will be available in single-dose 1-ml vials, as well as in 5- and 10-ml multi-dose vials. Thr market size for the product was $146 million for the 12 months ended October 2017, according to IQVIA data.

“We are very pleased to launch the only generic injectable of triamcinolone, bringing this affordable medication to patients and healthcare providers,” Amneal Biosciences president Charles Lucarelli said. “We will continue to focus on expanding our portfolio to provide quality generic injectables to our healthcare system.”